ClinicalTrials.gg
CompletedNCT02175758Updated Apr 30, 2019Results posted

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

A Phase 2 interventional study of SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 36 sites in 8 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
34th of 94
106 · median 75
Started
2014
with 10 others
Phase 2
31 of 94
none open now
Registered
26th of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 34th largest by enrollment, is one of 11 that started in 2014, is one of 31 in phase 2, and was the 26th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

This study will have two parts as follows:

The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric participants. The PK Lead-in Phase will also evaluate the safety and tolerability of 7 days of dosing of SOF+ribavirin (RBV) in HCV-infected pediatric participants.

The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate SOF dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the Treatment Phase with no interruption of study drug administration. The Treatment Phase will evaluate the antiviral efficacy, safety, and tolerability of SOF+RBV for 12 or 24 weeks in pediatric participants with genotype 2 or 3 HCV infection, respectively.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Consent of parent or legal guardian required
  • Chronic infection genotype 2 or 3
  • Screening laboratory values within defined thresholds
  • PK Lead-in only: all individuals must be treatment naive

Key Exclusion Criteria:

  • History of illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
  • Co-infection with , acute hepatitis A virus, or virus
  • Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)
  • Pregnant or nursing females
  • Known to study medication
  • Use of any prohibited concomitant medications as within 28 days of the Day 1 visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)

    Participants between 12 to \< 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)

    Participants between 12 to \< 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)

    Participants between 6 to \< 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)

    Participants between 6 to \< 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)

    Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)

    Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.

    Drug: SOF · Drug: RBV

Interventions

  • DrugSOF

    SOF administered orally once daily

    Also known as: Sovaldi®, GS-7977

  • DrugRBV

    RBV oral solution or capsules will be administered orally in a divided daily dose based on weight

    Also known as: REBETOL®

06

What researchers measure

Primary outcomes

  1. For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: 6 to < 18 years of age: predose, 0.5, 1, 2, 3, 4, 8, and 12 hours postdose on Day 7; 3 to < 6 years of age: predose, 2, 4, 8, and 12 hours postdose on Day 7

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase

    Time frame: Up to 24 weeks

  3. For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

Secondary outcomes

  1. For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA

    Time frame: Baseline; Weeks 1, 2, 4, 8, and 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase

    Time frame: Up to Day 7

  3. For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  4. For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  5. For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough

    Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.

    Time frame: Up to 24 weeks

  6. For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse

    Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

  7. For the Treatment Phase, Change From Baseline in HCV RNA

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)

  8. For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment

    Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)

  9. For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization

    ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit. One participant in the 3 to \< 6 Years Old 12 Weeks group had ALT \> ULN at Baseline, but had no other available data.

    Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4

  10. For the Treatment Phase, Change From Baseline in Height

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24

  11. For the Treatment Phase, Change From Baseline in Weight

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24

  12. For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  13. For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  14. For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  15. For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  16. For the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules

    Participants were asked if they were able to taste the SOF oral granules.

    Time frame: Day 1

07

Results

Posted Apr 30, 2019

Participant flow

Participants were enrolled at study sites in Australia, Europe, Russia, New Zealand, and the United States. The first participant was screened on 07 July 2014. The last study visit occurred on 13 September 2018.

PK Lead-in Phase
Participant flow — PK Lead-in Phase
Milestone12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Started4621048
Completed4621048
Not completed000000
Treatment Phase
Participant flow — Treatment Phase
Milestone12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Started1339132858
Completed1338132848
Not completed010010
Withdrew: Lost to follow-up010000
Withdrew: Adverse event000010

Outcome measures

PrimaryFor Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
6 to < 18 years of age: predose, 0.5, 1, 2, 3, 4, 8, and 12 hours postdose on Day 7; 3 to < 6 years of age: predose, 2, 4, 8, and 12 hours postdose on Day 7
Reported as:
Mean · h*ng/mL
For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)
h*ng/mLPK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 or 24 WeeksPK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 or 24 WeeksPK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)9106.0 ± 2601.967651.2 ± 1723.3210293.7 ± 1860.57
Statistical analysis
  • PK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks · Percentage geometric mean ratio: 129.48 · 90% CI 109.96 to 152.48
  • PK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks · Percentage geometric mean ratio: 109.80 · 90% CI 93.25 to 129.29
  • PK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks · Percentage geometric mean ratio: 149.67 · 90% CI 127.12 to 176.21
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase000020.00
PrimaryFor the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participants12 to < 18 Years Old (Total) - SOF+RBV 12 or 24 Weeks3 to < 12 Years Old (Total) - SOF+RBV 12 or 24 Weeks12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)98.1 (89.7 to 100.0)98.1 (90.1 to 100.0)100.0 (75.3 to 100.0)97.4 (86.5 to 99.9)100.0 (75.3 to 100.0)100.0 (87.7 to 100.0)80.0 (28.4 to 99.5)100.0 (63.1 to 100.0)
Statistical analysis
  • 12 to < 18 Years Old (Total) - SOF+RBV 12 or 24 Weeks · 2-sided exact 1-sample binomial test · p = <0.001
  • 3 to < 12 Years Old (Total) - SOF+RBV 12 or 24 Weeks · 2-sided exact 1-sample binomial test · p = <0.001
SecondaryFor Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
Time frame:
Baseline; Weeks 1, 2, 4, 8, and 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Reported as:
Mean · log10 IU/mL
For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
log10 IU/mLPK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 WeeksPK Lead-in: 12 to < 18 Years Old - SOF+RBV 24 WeeksPK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 WeeksPK Lead-in: 6 to < 12 Years Old - SOF+RBV 24 WeeksPK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 WeeksPK Lead-in: 3 to < 6 Years Old - SOF+RBV 24 Weeks
Change at Week 1-3.98 ± 1.056-4.23 ± 0.765-3.82 ± 0.447-3.78 ± 1.234-4.12 ± 0.632-3.53 ± 0.347
Change at Week 2-4.84 ± 0.743-4.34 ± 0.758-4.92 ± 0.674-4.56 ± 1.553-4.31 ± 0.846-3.94 ± 0.422
Change at Week 4-4.84 ± 0.743-4.34 ± 0.758-4.92 ± 0.674-4.60 ± 1.686-4.42 ± 1.006-3.97 ± 0.453
Change at Week 8-4.84 ± 0.743-4.34 ± 0.758-4.92 ± 0.674-4.61 ± 1.700-4.52 ± 1.177-3.97 ± 0.453
Change at Week 12-4.84 ± 0.743-4.34 ± 0.758-4.92 ± 0.674-4.61 ± 1.700-4.52 ± 1.177-3.97 ± 0.453
Change at Week 16—-4.34 ± 0.758—-4.61 ± 1.700—-3.97 ± 0.453
Change at Week 20—-4.34 ± 0.758—-4.61 ± 1.700—-3.97 ± 0.453
Change at Week 24—-4.34 ± 0.758—-4.61 ± 1.700—-3.97 ± 0.453
SecondaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
Time frame:
Up to Day 7
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
percentage of participantsPK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 or 24 WeeksPK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 or 24 WeeksPK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase000
SecondaryFor the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)100.0 (75.3 to 100.0)100.0 (91.0 to 100.0)100.0 (75.3 to 100.0)100.0 (87.7 to 100.0)80.0 (28.4 to 99.5)100.0 (63.1 to 100.0)
SecondaryFor the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)100.0 (75.3 to 100.0)97.4 (86.5 to 99.9)100.0 (75.3 to 100.0)100.0 (87.7 to 100.0)80.0 (28.4 to 99.5)100.0 (63.1 to 100.0)
SecondaryFor the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough

Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough000000
SecondaryFor the Treatment Phase, Percentage of Participants Experiencing Viral Relapse

Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse000000
SecondaryFor the Treatment Phase, Change From Baseline in HCV RNA
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Reported as:
Mean · log10 IU/mL
For the Treatment Phase, Change From Baseline in HCV RNA
log10 IU/mL12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Change at Week 1-4.25 ± 0.986-4.12 ± 0.733-4.12 ± 0.692-3.88 ± 0.928-4.12 ± 0.632-3.53 ± 0.347
Change at Week 2-4.74 ± 0.980-4.86 ± 0.702-4.55 ± 0.812-4.51 ± 1.102-4.31 ± 0.846-3.94 ± 0.422
Change at Week 4-4.74 ± 0.980-5.01 ± 0.760-4.68 ± 0.843-4.56 ± 1.171-4.42 ± 1.006-3.97 ± 0.453
Change at Week 8-4.74 ± 0.980-5.02 ± 0.771-4.68 ± 0.843-4.54 ± 1.191-4.52 ± 1.177-3.97 ± 0.453
Change at Week 12-4.74 ± 0.980-5.02 ± 0.771-4.68 ± 0.843-4.57 ± 1.178-4.52 ± 1.177-3.97 ± 0.453
Change at Week 16—-5.02 ± 0.771—-4.57 ± 1.178—-3.97 ± 0.453
Change at Week 20—-5.02 ± 0.771—-4.57 ± 1.178—-3.97 ± 0.453
Change at Week 24—-5.02 ± 0.771—-4.57 ± 1.178—-3.97 ± 0.453
SecondaryFor the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
Time frame:
Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Week 130.8 (9.1 to 61.4)30.8 (17.0 to 47.6)46.2 (19.2 to 74.9)39.3 (21.5 to 59.4)50.0 (6.8 to 93.2)37.5 (8.5 to 75.5)
Week 2100.0 (75.3 to 100.0)74.4 (57.9 to 87.0)76.9 (46.2 to 95.0)78.6 (59.0 to 91.7)75.0 (19.4 to 99.4)87.5 (47.3 to 99.7)
Week 4100.0 (75.3 to 100.0)92.3 (79.1 to 98.4)100.0 (75.3 to 100.0)96.4 (81.7 to 99.9)75.0 (19.4 to 99.4)100.0 (63.1 to 100.0)
Week 8100.0 (75.3 to 100.0)100.0 (91.0 to 100.0)100.0 (75.3 to 100.0)96.4 (81.7 to 99.9)100.0 (39.8 to 100.0)100.0 (63.1 to 100.0)
Week 12100.0 (75.3 to 100.0)100.0 (91.0 to 100.0)100.0 (75.3 to 100.0)100.0 (87.7 to 100.0)100.0 (39.8 to 100.0)100.0 (63.1 to 100.0)
Week 16—100.0 (91.0 to 100.0)—100.0 (87.7 to 100.0)—100.0 (63.1 to 100.0)
Week 20—100.0 (91.0 to 100.0)—100.0 (87.7 to 100.0)—100.0 (63.1 to 100.0)
Week 24—100.0 (91.0 to 100.0)—100.0 (87.7 to 100.0)—100.0 (63.1 to 100.0)
SecondaryFor the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization

ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit. One participant in the 3 to \< 6 Years Old 12 Weeks group had ALT \> ULN at Baseline, but had no other available data.

Time frame:
Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
percentage of participants12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Week 150.063.625.075.0—100.0
Week 2100.090.9100.093.3—100.0
Week 4100.095.5100.0100.0—100.0
Week 8100.095.5100.0100.0—100.0
Week 12100.0100.0100.0100.0—100.0
Week 16—100.0—100.0—100.0
Week 20—100.0—100.0—100.0
Week 24—100.0—100.0—100.0
Posttreatment Week 4100.0100.0100.0100.0—100.0
SecondaryFor the Treatment Phase, Change From Baseline in Height
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
Reported as:
Mean · centimeters
For the Treatment Phase, Change From Baseline in Height
centimeters12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Change at Week 10.1 ± 1.100.0 ± 0.570.0 ± 0.570.0 ± 0.730.3 ± 1.120.3 ± 0.75
Change at Week 20.1 ± 1.07-0.1 ± 0.590.1 ± 0.660.0 ± 0.540.7 ± 1.090.3 ± 0.50
Change at Week 40.2 ± 1.200.2 ± 0.780.3 ± 0.670.4 ± 0.740.9 ± 0.870.5 ± 0.67
Change at Week 80.3 ± 1.270.2 ± 0.851.0 ± 1.000.4 ± 0.620.9 ± 0.720.8 ± 0.51
Change at Week 120.5 ± 1.680.3 ± 0.950.8 ± 0.810.7 ± 0.681.5 ± 0.451.7 ± 1.84
Change at Week 16—0.4 ± 0.91—1.1 ± 0.93—1.8 ± 0.79
Change at Week 20—0.5 ± 1.10—1.6 ± 1.15—2.5 ± 1.01
Change at Week 24—0.8 ± 1.54—2.1 ± 0.88—2.7 ± 1.05
Change at Posttreatment Week 40.5 ± 1.790.9 ± 1.701.4 ± 0.802.6 ± 1.171.6 ± 0.913.5 ± 0.85
Change at Posttreatment Week 121.4 ± 1.651.3 ± 1.902.4 ± 1.023.8 ± 1.302.8 ± 1.814.0 ± 0.95
Change at Posttreatment Week 241.6 ± 1.891.8 ± 2.834.2 ± 1.115.1 ± 1.595.0 ± 1.615.7 ± 1.27
SecondaryFor the Treatment Phase, Change From Baseline in Weight
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
Reported as:
Mean · kilograms
For the Treatment Phase, Change From Baseline in Weight
kilograms12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Change at Week 1-0.7 ± 1.28-0.4 ± 1.360.2 ± 0.820.0 ± 0.550.2 ± 0.10-0.2 ± 0.51
Change at Week 2-0.2 ± 0.87-0.3 ± 0.990.3 ± 1.080.0 ± 0.640.5 ± 0.21-0.1 ± 0.50
Change at Week 4-0.2 ± 1.67-0.1 ± 1.150.4 ± 0.900.1 ± 0.900.0 ± 0.22-0.1 ± 0.49
Change at Week 8-0.5 ± 2.390.0 ± 1.530.6 ± 1.570.1 ± 1.210.3 ± 0.140.0 ± 0.55
Change at Week 12-0.4 ± 2.62-0.1 ± 2.010.9 ± 2.150.5 ± 1.350.3 ± 0.220.1 ± 0.85
Change at Week 16—0.2 ± 2.35—0.6 ± 1.34—0.1 ± 0.76
Change at Week 20—0.1 ± 2.65—0.9 ± 1.59—0.4 ± 0.86
Change at Week 24—0.5 ± 3.13—1.2 ± 1.91—0.4 ± 1.03
Change at Posttreatment Week 4-0.3 ± 3.190.9 ± 3.241.2 ± 2.201.3 ± 2.190.5 ± 0.270.7 ± 1.05
Change at Posttreatment Week 120.9 ± 2.692.1 ± 3.732.1 ± 3.282.2 ± 2.211.0 ± 0.880.9 ± 1.12
Change at Posttreatment Week 242.5 ± 4.983.0 ± 4.623.8 ± 3.673.5 ± 2.421.3 ± 1.101.7 ± 1.28
SecondaryFor the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Participants12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
End of Treatment — No Change23103
End of Treatment — Increase810
End of Treatment — Decrease000
Posttreatment Week 12 — No Change2093
Posttreatment Week 12 — Increase1020
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change2093
Posttreatment Week 24 — Increase1120
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
Participants12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
End of Treatment — No Change24113
End of Treatment — Increase700
End of Treatment — Decrease000
Posttreatment Week 12 — No Change21103
Posttreatment Week 12 — Increase910
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change2093
Posttreatment Week 24 — Increase1120
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Participants12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
End of Treatment — No Change20248
End of Treatment — Increase160
End of Treatment — Decrease000
Posttreatment Week 12 — No Change18238
Posttreatment Week 12 — Increase260
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change18228
Posttreatment Week 24 — Increase280
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
Participants12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
End of Treatment — No Change20248
End of Treatment — Increase150
End of Treatment — Decrease010
Posttreatment Week 12 — No Change17248
Posttreatment Week 12 — Increase350
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change16198
Posttreatment Week 24 — Increase4110
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules

Participants were asked if they were able to taste the SOF oral granules.

Time frame:
Day 1
Reported as:
Number · percentage of participants
For the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules
percentage of participants12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks
Able to Taste SOF Granules: Yes042.975.0
Able to Taste SOF Granules: No100.057.125.0

Adverse events

Collected over Adverse Events (AEs): First dose date up to Week 12 or 24 (depending on group) plus 30 days (includes AEs occurring during the PK Lead-in Phase); All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 to < 18 Years Old - SOF+RBV 12 Weeks0/13 (0%)0/13 (0%)12/13 (92.3%)
12 to < 18 Years Old - SOF+RBV 24 Weeks0/39 (0%)0/39 (0%)27/39 (69.2%)
6 to < 12 Years Old - SOF+RBV 12 Weeks0/13 (0%)0/13 (0%)9/13 (69.2%)
6 to < 12 Years Old - SOF+RBV 24 Weeks0/28 (0%)0/28 (0%)24/28 (85.7%)
3 to < 6 Years Old - SOF+RBV 12 Weeks0/5 (0%)0/5 (0%)5/5 (100%)
3 to < 6 Years Old - SOF+RBV 24 Weeks0/8 (0%)1/8 (12.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
Event12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
Accidental overdoseInjury, poisoning and procedural complications0/130/390/130/280/51/8
Most frequent other events
Showing 10 of 79
Most frequent other events
Event12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 Weeks
VomitingGastrointestinal disorders1/133/392/1311/283/53/8
DiarrhoeaGastrointestinal disorders2/131/391/133/282/53/8
Decreased appetiteMetabolism and nutrition disorders1/132/392/132/280/53/8
HeadacheNervous system disorders3/139/394/138/280/50/8
NauseaGastrointestinal disorders3/1311/390/134/280/51/8
Arthropod biteInjury, poisoning and procedural complications0/130/390/130/280/52/8
CoughRespiratory, thoracic and mediastinal disorders0/133/391/137/281/50/8
FatigueGeneral disorders0/134/393/135/281/51/8
Abdominal pain upperGastrointestinal disorders2/132/391/130/281/50/8
PyrexiaGeneral disorders0/130/390/134/281/50/8

Baseline characteristics

Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
Mean15 ± 1.915 ± 1.98 ± 2.19 ± 1.74 ± 0.85 ± 0.811 ± 4.2
Sex: Female, Male
Sex: Female, Male(Participants)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
Female51610204661
Male823381245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
Hispanic or Latino0224109
Not Hispanic or Latino133611234895
Unknown or Not Reported0101002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
Race — White11369203685
Race — Asian01260110
Race — Other0122117
Race — Black or African American2000103
Race — Native Hawaiian or Pacific Islander0100001
Region of Enrollment
Region of Enrollment(Participants)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
New Zealand0101002
Belgium0011002
United States8118104546
Italy34210111
United Kingdom02171112
Australia0215019
Germany0403007
Russia215000017
HCV RNA Category
HCV RNA Category(Participants)12 to < 18 Years Old - SOF+RBV 12 Weeks12 to < 18 Years Old - SOF+RBV 24 Weeks6 to < 12 Years Old - SOF+RBV 12 Weeks6 to < 12 Years Old - SOF+RBV 24 Weeks3 to < 6 Years Old - SOF+RBV 12 Weeks3 to < 6 Years Old - SOF+RBV 24 WeeksTotal
< 800,000 IU/mL5137152850
≥ 800,000 IU/mL8266133056
08

Study locations

36 sites
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Gainesville, Florida, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Westmead, New South Wales, Australia
  • Melbourne, Victoria, Australia
  • New Lambton Heights, Australia
  • Brussels, Belgium
  • Wuppertal, Nordrhein-westfalen, Germany
  • Berlin, Germany
  • Bologna, Italy
  • Firenze, Italy
  • Milano, Italy
  • Padova, Italy
  • San Giovanni Rotondo, Italy
  • Torino, Italy
  • Auckland, New Zealand
  • Moscow, Russian Federation
  • Novokuznetsk, Russian Federation
  • Saint-Petersburg, Russian Federation
  • Tolyatti, Russian Federation
  • Birmingham, United Kingdom
  • Leeds, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Kirby B, German P, Kanwar B, Ni L, Lakatos I, Ling J, Mathias A. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Adolescents [Poster 1707]. American Association for the Study of Liver Diseases (AASLD); 2015 November 13-17, San Francisco, USA. Hepatology 2015;62 (S1): 1040A-1041A
  • Garrison KL, Mathias A, Kersey K, Kanwar B, Ni L, Jain A, et al. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to <12 Years Old [Poster 878]. American Association for the Study of Liver Diseases (AASLD); 2016 11-15 November; Boston, MA. Hepatology 2016;64 (S1): 436A
  • Schwarz KB, Rosenthal P, Gonzales-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks Is Safe and Effective in Adolescents with Genotype 2 or Genotype 3 Chronic Hepatitis C Infection. Hepatology 2016; 63 (Suppl 1): abstract 706.
  • Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017 Oct;66(4):1102-1110. doi: 10.1002/hep.29278. Epub 2017 Aug 26. PubMed 28543053 ↗
  • Younossi ZM, Stepanova M, Schwarz KB, Wirth S, Rosenthal P, Gonzalez-Peralta R, Murray K, Henry L, Hunt S. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat. 2018 Apr;25(4):354-362. doi: 10.1111/jvh.12830. Epub 2017 Dec 26. PubMed 29193603 ↗
  • Rosenthal P, Schwarz KB, Gonzales-Peralta RP, Lin CH, Kelly DA, Nightingale S, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks Is Safe and Effective in Children 3 to <12 Years Old with Genotype 2 or Genotype 3 Chronic Hepatitis C Infection. Hepatology 2018; 68 (Suppl 1): abstract 1844.
  • Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, Balistreri WF, Bansal S, Jonas MM, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Davison S, Feiterna-Sperling C, Gillis LA, Indolfi G, Sokal EM, Murray KF, Wirth S. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology. 2020 Jan;71(1):31-43. doi: 10.1002/hep.30821. Epub 2019 Aug 13. PubMed 31222783 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jun 2018, 47 months.

Results were first posted in Apr 2019, 10 months after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 47 months is above that.

Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 26, 2014
StartActual
Jul 7, 2014
Primary completionActual
Jun 21, 2018
CompletionActual
Sep 13, 2018
Results first posted
Apr 30, 2019
Last update
Apr 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02175758
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Jul 7, 2014
Primary completion
Jun 21, 2018
Completion
Sep 13, 2018
Results posted
Apr 30, 2019
Last update
Apr 30, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion